Dabrafenib (GSK2118436)

Catalog No.S2807

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Cited by 21 Publications

Nature, 2017, 550(7674):133-136

PubMed: 28953887

Cell, 2018, 173(6):1413-1425

PubMed: 29754815

Nature, 2017, 551(7679):247-250

PubMed: 29088702

Science, 2016, 352(6282):189-96

PubMed: 27124452

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297

Leukemia, 2016, 30(4):937-46

PubMed: 26582644

Cancer research, 2018, 78(2):542-557

PubMed: 29180473

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049
Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720

Transl Res, 2014, 164(5):411-23

PubMed: 25016932

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801

J Immunother, 2015, 38(1):12-23

PubMed: 25415284

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720

The University of Texas, 2014, Lizee S

PubMed:

9 Customer Reviews

BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.
Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.
Braf−/− ER(TM)-HRAS(G12V) MEFs were transduced with retroviral constructs encoding the indicated BRAF proteins and treated with 4-HT to release oncogenic RAS, or ethanol as a control. Following incubation with 1 μM vemurafenib, 1 μM dabrafenib or DMSO as a control for 4 h, cells were subjected to western blot analysis with the indicated antibodies.

Leukemia, 2016, 30(4):937-46. Dabrafenib (GSK2118436) purchased from Selleck.

Western blots for untreated, early, and late tumors.

Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.
Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.
Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MW\LbY5ie2ViQYPzZZk>				MlnmTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG\|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch\|ryP	NG\VXWIzPDlyME[3Ny=>
SK-MEL-28	NYTKeYsyU2mwYYPlJGF{e2G7		M1\aOlEhcA>?		MlvvTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJGVTUyCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFA1KM7:TR?=	NXfpSlNYOjR7MEC2O\|M>
HepG2	MnTwT4lv[XOnIFHzd4F6				NFzlNlJKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1?	Ml\5NlQ6ODB4N{O=
COLO205	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfi[45FUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPNlA2KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xODdizszN	NUTGWYlVOjR7MEC2O\|M>
HepG2	NYDxfnlLTnWwY4Tpc44hSXO\|YYm=		NFXUeXM1PSCvaX6=	MWTEUXNQ	MUPJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JI9lgXO\|ZYmgZoxwfCC\|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch\|ryP	MVyyOFkxODZ5Mx?=
HFF	M{m4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f1XFExKM7:TR?=	MW[3NkBp	NHXIb25FVVOR	Mkj2TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKGi3bXHuJGhHTiClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEJvUnHmJJdqfGhiSVO1NEBw\iB\|IN88US=>	NF21[GYzOzh2NECzPC=>
SK-MEL-28	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\afFExKM7:TR?=	MnvBO\|IhcA>?	MonSSG1UVw>?	MYrJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN	NIXpcJQzOzh2NECzPC=>
A375P-F11	MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjifYdLOTBizszN	NV\QR3B1PzJiaB?=	M3LGO2ROW09?	M33GbmlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0>	NH;XbHMzOzh2NECzPC=>
MALME-3M	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TxdFExKM7:TR?=	NYTZRmRrPzJiaB?=	MXfEUXNQ	NEnLVHJKSzVyPUGgcm0>	MWqyN\|g1PDB\|OB?=
UACC-62	NV3Fb5Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvWXnZiOTBizszN	MlzoO\|IhcA>?	MnjiSG1UVw>?	MX7JR\|UxRTFibl2=	Ml7KNlM5PDRyM{i=
C32TG	M{fGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHEc\|l3OTBizszN	NXHBV2llPzJiaB?=	MnjRSG1UVw>?	MWrJR\|UxRTFibl2=	NYjWUHdVOjN6NESwN\|g>
SK-MEL-1	M{jrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{juSlExKM7:TR?=	MnfGO\|IhcA>?	NI\YdIJFVVOR	NUj6VmtrUUN3ME2yJI5O	MV2yN\|g1PDB\|OB?=
M14	NYj4XXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37GNFExKM7:TR?=	MYi3NkBp	Mn\DSG1UVw>?	MVHJR\|UxRTJibl2=	NYLlNW92OjN6NESwN\|g>
SK-MEL-28	M4PWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjSU3hlOTBizszN	MnrOO\|IhcA>?	MmHqSG1UVw>?	M2[3[GlEPTB;MzDuUS=>	NYe2UWI4OjN6NESwN\|g>
A375	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkC5NVAh\|ryP	NFe1b4Y4OiCq	MYPEUXNQ	M1jvOWlEPTB;NDDuUS=>	M4\rTVI{QDR2MEO4
DU-4475	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVyxNEDPxE1?	M4n1blczKGh?	M2rGbmROW09?	MWDJR\|UxRTVibl2=	NW\3UJd5OjN6NESwN\|g>
UACC-257	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLKVXFuOTBizszN	MUi3NkBp	MX7EUXNQ	NWPrPI9OUUN3ME22JI5O	MXSyN\|g1PDB\|OB?=
Colo 205	M1Tyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jITVExKM7:TR?=	NYD4WGVUPzJiaB?=	NG\oNJpFVVOR	MlrpTWM2OD15IH7N	NGr5NWozOzh2NECzPC=>
SK-MEL-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjvNVAh\|ryP	NGXsNm44OiCq	MljESG1UVw>?	M3yxfmlEPTB;NzDuUS=>	MYCyN\|g1PDB\|OB?=
SH-4	NETj[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWS3VFFlOTBizszN	NFG0NY44OiCq	MlXPSG1UVw>?	NEnVWlJKSzVyPUigcm0>	M3PFWVI{QDR2MEO4
A101D	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HmTVExKM7:TR?=	MnnWO\|IhcA>?	M2rhfmROW09?	M{LRbmlEPTB;OTDuUS=>	NE\kZWwzOzh2NECzPC=>
ES-2	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDIdnVlOTBizszN	M1j6XFczKGh?	NHnTTHNFVVOR	NVrLOVFkUUN3ME21N{BvVQ>?	MmnLNlM5PDRyM{i=
HT-29	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jTOlExKM7:TR?=	MVy3NkBp	MnjUSG1UVw>?	MmL3TWM2OD14NjDuUS=>	Mmf6NlM5PDRyM{i=
SW1417	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGxNEDPxE1?	NEj4SVc4OiCq	NWf3Smw1TE2VTx?=	MVTJR\|UxRTF3ODDuUS=>	NIO3RmgzOzh2NECzPC=>
SW872	M1jER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPNWHJxOTBizszN	Mk\pO\|IhcA>?	M1vIOmROW09?	MYfJR\|UxRTN5NzDuUS=>	MUWyN\|g1PDB\|OB?=
RKO	NXH5NVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjZNVAh\|ryP	MnrkO\|IhcA>?	MlnUSG1UVw>?	MUjJR\|UxRTJwNUKyJO69VQ>?	MVuyN\|g1PDB\|OB?=
A673	NGrHepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXwNVAh\|ryP	NFfJWYQ4OiCq	M1vt[2ROW09?	MY\JR\|UxRTFyIN88US=>	NIGxS3czOzh2NECzPC=>
GCT	Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVyxNEDPxE1?	MVu3NkBp	NGH1UoFFVVOR	NYT2OW9xUUN3ME2xNEDPxE1?	MUCyN\|g1PDB\|OB?=
WM-115	M{i5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1SwWFExKM7:TR?=	NIWyWXY4OiCq	NV\TbHFGTE2VTx?=	MkfMTWM2OD13IH7N	MV2yN\|g1PDB\|OB?=
YUMAC	NUC2SodJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITOeFcyOCEQvF2=	MkfMO\|IhcA>?	MlL5SG1UVw>?	NFu0[G5KSzVyPUWgcm0>	NGW3eFYzOzh2NECzPC=>
OV-90	NYDWdHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVmxNEDPxE1?	MWC3NkBp	NH71TVVFVVOR	NUKzOVhKUUN3ME2yPUBvVQ>?	NVvJVpJwOjN6NESwN\|g>
NCI-H508	NI[ydHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17kSlExKM7:TR?=	MWW3NkBp	NH7YfllFVVOR	NV7XNJF1UUN3ME2xNEDPxE1?	MnjhNlM5PDRyM{i=
MDA-MB-231	M2rVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGxNEDPxE1?	M2\DZlczKGh?	MWTEUXNQ	NHv3RnFKSzVyPUGwJO69VQ>?	MknPNlM5PDRyM{i=
SW756	MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrZc3oyOCEQvF2=	MoHkO\|IhcA>?	NH;BeFZFVVOR	MX7JR\|UxRTFyIN88US=>	NVz4TYhPOjN6NESwN\|g>
SW-837	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoWyNVAh\|ryP	M1\lT\|czKGh?	M1Plc2ROW09?	MmnPTWM2OD1zMDFOwG0>	MlLkNlM5PDRyM{i=
UMUC-3	M4PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOxNEDPxE1?	NGHM[2g4OiCq	M3HJXWROW09?	MkjvTWM2OD1zMDFOwG0>	MmrKNlM5PDRyM{i=
LS-174T	NVrUfZJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LqN\|ExKM7:TR?=	NXTqdVJLPzJiaB?=	NYK2OGdmTE2VTx?=	NYLWV4ZUUUN3ME2xNEDPxE1?	NWHHc2t1OjN6NESwN\|g>
A549	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxNEDPxE1?	MXm3NkBp	NGf1NZZFVVOR	M{XOdmlEPTB;MUCg{txO	MmrENlM5PDRyM{i=
SHP-77	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\Zb\|FGOTBizszN	NYPDV\|hvPzJiaB?=	MUPEUXNQ	MXLJR\|UxRTFyIN88US=>	MnuwNlM5PDRyM{i=
SW480	NGmxZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\mTogyOCEQvF2=	NVfjbYRVPzJiaB?=	MkHMSG1UVw>?	M4DJZ2lEPTB;MUCg{txO	NVnseJk5OjN6NESwN\|g>
DLD-1	M33rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNEDPxE1?	M{jzblczKGh?	NHu1Z2xFVVOR	MVfJR\|UxRTFyIN88US=>	M4LQ[FI{QDR2MEO4
HCT-116	NITDOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13Vd\|ExKM7:TR?=	MV:3NkBp	MmnXSG1UVw>?	M4PVSGlEPTB;MUCg{txO	M{jaT\|I{QDR2MEO4
NCI-H747	M1m0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzpNVAh\|ryP	MUG3NkBp	MY\EUXNQ	M17NOGlEPTB;MUCg{txO	NYTUcZlnOjN6NESwN\|g>
T-84	NHq0OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n6[\|ExKM7:TR?=	M4HZRVczKGh?	MX\EUXNQ	NUPhTJBvUUN3ME2xNEDPxE1?	MXOyN\|g1PDB\|OB?=
NCI-H460	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUe4THFIOTBizszN	MlXpO\|IhcA>?	MWHEUXNQ	NIDLTXpKSzVyPUGwJO69VQ>?	MVeyN\|g1PDB\|OB?=
Calu-6	M{j2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4L6T\|ExKM7:TR?=	NVXoRpczPzJiaB?=	MlmzSG1UVw>?	NH\uXI1KSzVyPUGwJO69VQ>?	NGH4T5MzOzh2NECzPC=>
HCC-2998	NX3aN2IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW[xNEDPxE1?	NWHwVXhxPzJiaB?=	NFzQRmJFVVOR	M2ThSmlEPTB;MUCg{txO	M4XuPVI{QDR2MEO4
LS1034	MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFqzXpgyOCEQvF2=	MUO3NkBp	NHLsN3dFVVOR	MnzSTWM2OD1zMDFOwG0>	NHTEZ3IzOzh2NECzPC=>
CHP-212	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjZNVAh\|ryP	MYK3NkBp	M1;3NGROW09?	NUL5V2VtUUN3ME2xNEDPxE1?	MUiyN\|g1PDB\|OB?=
SK-N-AS	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSxNEDPxE1?	MkfqO\|IhcA>?	M4XzVWROW09?	MWHJR\|UxRTFyIN88US=>	M3zsO\|I{QDR2MEO4
BFTC-905	NGD1So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqxRpF2OTBizszN	Mon2O\|IhcA>?	Mlv1SG1UVw>?	MnLVTWM2OD1zMDFOwG0>	MkXaNlM5PDRyM{i=
HuT78	NIK0[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[4OY4yOCEQvF2=	Ml3pO\|IhcA>?	NI\tOJpFVVOR	MXzJR\|UxRTV{IH7N	M3j4TVI{QDR2MEO4
RPMI-8226	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LPO\|ExKM7:TR?=	NVS1WYVEPzJiaB?=	MnnRSG1UVw>?	MYHJR\|UxRTJ4MzDuUS=>	NF70WpkzOzh2NECzPC=>
BC-3	MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjyNVAh\|ryP	NXvlb4w1PzJiaB?=	MnjySG1UVw>?	MVPJR\|UxRTJ5NzDuUS=>	NYXr[4UyOjN6NESwN\|g>
ACHN	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXKxNEDPxE1?	NWe3TlFyPzJiaB?=	NVjZ[m5FTE2VTx?=	MnvyTWM2OD1{OUSgcm0>	MlTXNlM5PDRyM{i=
JRT3-T35	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSxNEDPxE1?	MXW3NkBp	NHfoeXRFVVOR	MlHsTWM2OD1{OUWgcm0>	NFOyR4QzOzh2NECzPC=>
SK-MES-1	NXnh[Xh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHKdJAyOCEQvF2=	M3PYcFczKGh?	MUnEUXNQ	NW[4d2NkUUN3ME2zNlkhdk1?	MlHxNlM5PDRyM{i=
CESS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGxNEDPxE1?	M3;SOFczKGh?	NV:4OFdCTE2VTx?=	NWLEd41YUUN3ME20PVchdk1?	NYn1VlB[OjN6NESwN\|g>
H4	M{S1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fkPVExKM7:TR?=	Mn\kO\|IhcA>?	NIL2OpJFVVOR	NXn1VlV5UUN3ME22NVkhdk1?	MYSyN\|g1PDB\|OB?=
BC-1	NHjpcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXwT3UyOCEQvF2=	Mo\aO\|IhcA>?	MmHSSG1UVw>?	NVjD[oZwUUN3ME23NFQhdk1?	Mkn6NlM5PDRyM{i=
DB	NYTDdIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\FNVAh\|ryP	MlXnO\|IhcA>?	NEXyU3FFVVOR	M2\oXGlEPTB;OEezJI5O	NVfaUpBsOjN6NESwN\|g>
RPMI-6666	NFyxdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm2N\|NLOTBizszN	NWK5V252PzJiaB?=	NFjqTmxFVVOR	NY\YUIZTUUN3ME25Nlghdk1?	MoO4NlM5PDRyM{i=
MC/CAR	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWKzenZWOTBizszN	MXm3NkBp	MoTaSG1UVw>?	MUnJR\|UxRTFwMECyJO69VQ>?	M1PibFI{QDR2MEO4
SNU-1	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXu[nR[OTBizszN	M4\oWVczKGh?	Ml3XSG1UVw>?	NETMN5RKSzVyPUGuOVAyKM7:TR?=	NGG0XIkzOzh2NECzPC=>
CEM/C1	M{OxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjCenAyOCEQvF2=	Mm\6O\|IhcA>?	MWfEUXNQ	MULJR\|UxRTFwN{ezJO69VQ>?	NEjVNoUzOzh2NECzPC=>
GDM-1	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[xNEDPxE1?	M{TLSVczKGh?	NG\0[ZZFVVOR	NHfCe\|ZKSzVyPUGuPVk4KM7:TR?=	MVuyN\|g1PDB\|OB?=
HT-1080	NYfjeXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInYRWoyOCEQvF2=	MoG1O\|IhcA>?	M1;CRmROW09?	NYrER3ltUUN3ME2yMlAxPCEQvF2=	MViyN\|g1PDB\|OB?=
HL-60	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3MZ2QyOCEQvF2=	NX7wRlJjPzJiaB?=	MmLCSG1UVw>?	MVzJR\|UxRTJwMUe4JO69VQ>?	NELJPVEzOzh2NECzPC=>
C3A	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	NXn1eGt2PzJiaB?=	M4izT2ROW09?	NWj0Noo3UUN3ME21MlQyPCEQvF2=	NHL5SXEzOzh2NECzPC=>
MES-SA	NGW1[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLkPHoyOCEQvF2=	MXK3NkBp	NX3aSVJ3TE2VTx?=	MkLuTWM2OD14Lkm4PUDPxE1?	NGXB[\|QzOzh2NECzPC=>
22Rv1	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWGxNEDPxE1?	NFK2TlQ4OiCq	M1XNcGROW09?	MnW0TWM2OD1zMDFOwG0>	MnrzNlM5PDRyM{i=
647-V	NXznWW4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DVVVExKM7:TR?=	M4f0R\|czKGh?	NHS2TlhFVVOR	NGLCblRKSzVyPUGwJO69VQ>?	NGniVlgzOzh2NECzPC=>
786-O	NXLMWFI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjYTZFyOTBizszN	NYLUb3B2PzJiaB?=	M1v2c2ROW09?	NUC1S\|R1UUN3ME2xNEDPxE1?	M3:3fVI{QDR2MEO4
A172	NYS4bY02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSxNEDPxE1?	Mn22O\|IhcA>?	NHrC[ItFVVOR	M2XwZWlEPTB;MUCg{txO	MlTxNlM5PDRyM{i=
A204	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHK0OGsyOCEQvF2=	NH;se4c4OiCq	MoXDSG1UVw>?	M{Xt[WlEPTB;MUCg{txO	Mn7pNlM5PDRyM{i=
A427	NXHPT5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXKV5NEOTBizszN	M3mxRVczKGh?	NXXubVd1TE2VTx?=	NXfrZVJTUUN3ME2xNEDPxE1?	MoDXNlM5PDRyM{i=
A431	NGHxSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[1N3lNOTBizszN	MYC3NkBp	M2[xOmROW09?	Ml;aTWM2OD1zMDFOwG0>	MYmyN\|g1PDB\|OB?=
A2780	NX;2RpNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLuNVAh\|ryP	M2XNUFczKGh?	Mn7sSG1UVw>?	NETZcZdKSzVyPUGwJO69VQ>?	MWCyN\|g1PDB\|OB?=
ARH-77	NXLKU3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfYO4ljOTBizszN	MYC3NkBp	M1[1bmROW09?	NI[5WZZKSzVyPUGwJO69VQ>?	MVuyN\|g1PDB\|OB?=
Be(2)C	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fFNFExKM7:TR?=	MnLlO\|IhcA>?	M4PyRWROW09?	MWrJR\|UxRTFyIN88US=>	M4Lob\|I{QDR2MEO4
BT-20	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[xNEDPxE1?	MkPXO\|IhcA>?	NEnoVYxFVVOR	NEHSbldKSzVyPUGwJO69VQ>?	NHr1WpozOzh2NECzPC=>
BxPc3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[xNEDPxE1?	M{jhZVczKGh?	M3vnNGROW09?	NUG1V3ZnUUN3ME2xNEDPxE1?	M3zudVI{QDR2MEO4
C-4 I	NEnSXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrhRnFKOTBizszN	NYXBWHJWPzJiaB?=	MYTEUXNQ	NV;0cItUUUN3ME2xNEDPxE1?	MVGyN\|g1PDB\|OB?=
C33A	M4D5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFL3T5EyOCEQvF2=	M3LhelczKGh?	M1vqW2ROW09?	Ml31TWM2OD1zMDFOwG0>	M4ewfVI{QDR2MEO4
CAL-27	NI\I[\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGxNEDPxE1?	NXTC[\|hUPzJiaB?=	NIT0cYFFVVOR	MYLJR\|UxRTFyIN88US=>	NWLEfJFQOjN6NESwN\|g>
CAL-62	NIC0VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPyWVFvOTBizszN	MWq3NkBp	MlnSSG1UVw>?	MV3JR\|UxRTFyIN88US=>	Mm[wNlM5PDRyM{i=
Calu-3	NUP0b\|VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDXTXdJOTBizszN	Mof3O\|IhcA>?	MU\EUXNQ	MoDmTWM2OD1zMDFOwG0>	NWjjXGV3OjN6NESwN\|g>
CaOV3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;lVFExKM7:TR?=	Mkm4O\|IhcA>?	M3K4emROW09?	Moq4TWM2OD1zMDFOwG0>	NYHKWJJbOjN6NESwN\|g>
CGTHW1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDFNVAh\|ryP	NH\QWnA4OiCq	NVrIUXJJTE2VTx?=	NVPw[GR3UUN3ME2xNEDPxE1?	M4DDVVI{QDR2MEO4
CHL-1	NGnCbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorhNVAh\|ryP	MWq3NkBp	M{fDRmROW09?	MnPTTWM2OD1zMDFOwG0>	MVKyN\|g1PDB\|OB?=
Colo320DM	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEn4UlEyOCEQvF2=	M3;LXFczKGh?	NVzWVGt2TE2VTx?=	NGfOZoVKSzVyPUGwJO69VQ>?	MYCyN\|g1PDB\|OB?=
Colo704	M4XSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnizNVAh\|ryP	MUC3NkBp	MnXKSG1UVw>?	NUnpc3Z1UUN3ME2xNEDPxE1?	MVGyN\|g1PDB\|OB?=
COR-L23	M1\FWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXBNVAh\|ryP	M3;0PFczKGh?	MoTzSG1UVw>?	Ml3wTWM2OD1zMDFOwG0>	MWeyN\|g1PDB\|OB?=
CRO-AP2	M4\vVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fENFExKM7:TR?=	MkjWO\|IhcA>?	NIXNZnhFVVOR	MXvJR\|UxRTFyIN88US=>	NGewXG8zOzh2NECzPC=>
Daudi	M2PZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[xNEDPxE1?	M376TlczKGh?	NY\WWIx3TE2VTx?=	MUfJR\|UxRTFyIN88US=>	M3LtPFI{QDR2MEO4
DOTC 24510	MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjXdI4yOCEQvF2=	NVmzd3hmPzJiaB?=	MoLFSG1UVw>?	MX3JR\|UxRTFyIN88US=>	NWq3THc5OjN6NESwN\|g>
DU-145	NXvs[\|NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS0WVQ1OTBizszN	NH:1ZVI4OiCq	MkHrSG1UVw>?	M1zGN2lEPTB;MUCg{txO	M1mzWFI{QDR2MEO4
EB-3	NXvySHkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjlNVAh\|ryP	MW[3NkBp	Mlv6SG1UVw>?	NEjNRVVKSzVyPUGwJO69VQ>?	MWWyN\|g1PDB\|OB?=
EFM-19	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmxNEDPxE1?	M1:zOFczKGh?	M{XLe2ROW09?	M3[zTGlEPTB;MUCg{txO	MUiyN\|g1PDB\|OB?=
EKVX	NVTORVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXLNW0yOCEQvF2=	Mn7GO\|IhcA>?	MYXEUXNQ	MYfJR\|UxRTFyIN88US=>	NXHnV3lMOjN6NESwN\|g>
FaDu	NIHzZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxNEDPxE1?	M1XjbFczKGh?	NWqzdY86TE2VTx?=	NVnz[45mUUN3ME2xNEDPxE1?	NIC1N\|AzOzh2NECzPC=>
G401	M1[xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXQ[3UyOCEQvF2=	MVq3NkBp	Ml31SG1UVw>?	MXXJR\|UxRTFyIN88US=>	NHj6UnIzOzh2NECzPC=>
HCC-70	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LpXVExKM7:TR?=	NWDqVXUzPzJiaB?=	NXPjN2ptTE2VTx?=	M1TPeWlEPTB;MUCg{txO	NVTtOYpsOjN6NESwN\|g>
HCC-1954	NF;xO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuxNEDPxE1?	MX63NkBp	NFTzNotFVVOR	MXrJR\|UxRTFyIN88US=>	NHqyco8zOzh2NECzPC=>
Hela	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljQNVAh\|ryP	NXLPZYc5PzJiaB?=	M33GTGROW09?	NH[x[WxKSzVyPUGwJO69VQ>?	M32yelI{QDR2MEO4
Hep3B	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3l[VFHOTBizszN	NWG5flZsPzJiaB?=	NET6OJJFVVOR	MUXJR\|UxRTFyIN88US=>	MUiyN\|g1PDB\|OB?=
HMCB	M{nWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHRNVAh\|ryP	M37qZVczKGh?	NGjzPFVFVVOR	NWHEd4E5UUN3ME2xNEDPxE1?	NVj4dpVQOjN6NESwN\|g>
HN5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHi1XWYyOCEQvF2=	MlnZO\|IhcA>?	MkPMSG1UVw>?	MWPJR\|UxRTFyIN88US=>	M3S0ZVI{QDR2MEO4
HOS	NX7WNFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX73T5lrOTBizszN	NXvkflR3PzJiaB?=	MXzEUXNQ	NYjz[m9IUUN3ME2xNEDPxE1?	NUf0S4lCOjN6NESwN\|g>
HPAF-II	NUHk[oRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlr1NVAh\|ryP	MVm3NkBp	MkS5SG1UVw>?	NWDsfIpQUUN3ME2xNEDPxE1?	NVu3ToNFOjN6NESwN\|g>
Hs746.T	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX75XGhnOTBizszN	NGK4[VE4OiCq	MWfEUXNQ	MVXJR\|UxRTFyIN88US=>	M4ixT\|I{QDR2MEO4
HT	NEnzSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYexNEDPxE1?	MVW3NkBp	MWjEUXNQ	MmfjTWM2OD1zMDFOwG0>	MW[yN\|g1PDB\|OB?=
HT-3	M4H4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILRUlcyOCEQvF2=	MX23NkBp	MYjEUXNQ	NFfOWo9KSzVyPUGwJO69VQ>?	MWWyN\|g1PDB\|OB?=
HuNS-1	M{PLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoT5NVAh\|ryP	NW\We4dUPzJiaB?=	NXXMepFPTE2VTx?=	M1jaPWlEPTB;MUCg{txO	MWqyN\|g1PDB\|OB?=
IGROV1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jkbVExKM7:TR?=	NXvxUZQ3PzJiaB?=	NIHuSXBFVVOR	NInsU3pKSzVyPUGwJO69VQ>?	MoXLNlM5PDRyM{i=
J82	NGHvVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr4NJhTOTBizszN	NYLENlFKPzJiaB?=	M{DpPGROW09?	MUjJR\|UxRTFyIN88US=>	M3PSUFI{QDR2MEO4
JM1	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDiTZQyOCEQvF2=	MmDUO\|IhcA>?	M1XkTmROW09?	NFvOUHVKSzVyPUGwJO69VQ>?	NWPkN\|R{OjN6NESwN\|g>
Kato III	M136e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjsfYkyOCEQvF2=	Mo[5O\|IhcA>?	NF;mRXZFVVOR	MXnJR\|UxRTFyIN88US=>	MV6yN\|g1PDB\|OB?=
KHOS-240S	M{DoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTHfmsyOCEQvF2=	MnWwO\|IhcA>?	MkLGSG1UVw>?	NUXjN4lPUUN3ME2xNEDPxE1?	MnHKNlM5PDRyM{i=
KM-12	NInzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnNNVAh\|ryP	NWPMPXVoPzJiaB?=	NX3UPWlzTE2VTx?=	MmfqTWM2OD1zMDFOwG0>	M1nhUlI{QDR2MEO4
KPL-1	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\6NVAh\|ryP	NHLEZYI4OiCq	MVnEUXNQ	MXTJR\|UxRTFyIN88US=>	MoK3NlM5PDRyM{i=
KYSE-30	M4foWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF20[3UyOCEQvF2=	NUX4PGNVPzJiaB?=	NFLpeZhFVVOR	MVjJR\|UxRTFyIN88US=>	MmW2NlM5PDRyM{i=
LNCaP	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTVS5oyOCEQvF2=	M1PqclczKGh?	NXnqO2U1TE2VTx?=	NGTTO3ZKSzVyPUGwJO69VQ>?	M1ToVlI{QDR2MEO4
MCF-7	M1vrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojFNVAh\|ryP	NFHVcYo4OiCq	MmK1SG1UVw>?	Mlu0TWM2OD1zMDFOwG0>	M2HIZlI{QDR2MEO4
MC-IXC	NYLyVVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVixNEDPxE1?	NHSwc5c4OiCq	NFHXdmtFVVOR	M1fCWmlEPTB;MUCg{txO	MXKyN\|g1PDB\|OB?=
MDA-MB-175 VII	NWXHPIZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDoVIUyOCEQvF2=	NYfHPJpCPzJiaB?=	NX2yNYI1TE2VTx?=	NHPlOIVKSzVyPUGwJO69VQ>?	MoHJNlM5PDRyM{i=
MDA-MB-468	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4r5b\|ExKM7:TR?=	NEDqeY04OiCq	NYTk[IJoTE2VTx?=	MYTJR\|UxRTFyIN88US=>	NVjqTWZqOjN6NESwN\|g>
MiaPaCa	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fMOVExKM7:TR?=	MXe3NkBp	NYjpUHNPTE2VTx?=	NXvUZZdbUUN3ME2xNEDPxE1?	M{[0c\|I{QDR2MEO4
Molt-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNEDPxE1?	MnTNO\|IhcA>?	M4PZN2ROW09?	MnT0TWM2OD1zMDFOwG0>	NIrIZ3ozOzh2NECzPC=>
NCI-ADR/RES	NX74bmExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD3NVAh\|ryP	Ml;YO\|IhcA>?	M2PaPWROW09?	MUXJR\|UxRTFyIN88US=>	NUfsenNrOjN6NESwN\|g>
NCI-H69	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHKeoVYOTBizszN	MXi3NkBp	Mn\XSG1UVw>?	NX7kUnJHUUN3ME2xNEDPxE1?	MnLDNlM5PDRyM{i=
NCI-H82	NVnJboNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXiyV5hzOTBizszN	M2\YWlczKGh?	MX\EUXNQ	NGnWbnFKSzVyPUGwJO69VQ>?	NEX1VG4zOzh2NECzPC=>
NCI-N87	M2nLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M132Z\|ExKM7:TR?=	MVW3NkBp	MV;EUXNQ	M3vTRWlEPTB;MUCg{txO	M3rsVFI{QDR2MEO4
NCI-H146	NGm5RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUSxNEDPxE1?	NUfBNFlSPzJiaB?=	MXzEUXNQ	MkS2TWM2OD1zMDFOwG0>	Mm\qNlM5PDRyM{i=
NCI-H157	M4TldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3zNVAh\|ryP	M3nZN\|czKGh?	NHHCN5pFVVOR	NYryfmhpUUN3ME2xNEDPxE1?	M1ruRVI{QDR2MEO4
NCI-H187	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKxNEDPxE1?	M1PJOFczKGh?	NH:yRm5FVVOR	MULJR\|UxRTFyIN88US=>	MlPoNlM5PDRyM{i=
NCI-H209	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPWNVAh\|ryP	MkDwO\|IhcA>?	NYXCeVliTE2VTx?=	M1jKfGlEPTB;MUCg{txO	MV[yN\|g1PDB\|OB?=
NCI-H226	NGLNZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1n6SVExKM7:TR?=	MYS3NkBp	MUTEUXNQ	MlLvTWM2OD1zMDFOwG0>	M17TSlI{QDR2MEO4
NCI-H292	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fRZlExKM7:TR?=	NUjWVVg1PzJiaB?=	NHPWVplFVVOR	MoHqTWM2OD1zMDFOwG0>	NUS4RXRJOjN6NESwN\|g>
NCI-H322	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWOxNEDPxE1?	MXy3NkBp	NIKyVYZFVVOR	MVzJR\|UxRTFyIN88US=>	MlG5NlM5PDRyM{i=
NCI-H358	NU\VVG9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[xNEDPxE1?	MWe3NkBp	NWDuTFhITE2VTx?=	MnjvTWM2OD1zMDFOwG0>	NF7RV2ozOzh2NECzPC=>
NCI-H520	M{e0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jPfFExKM7:TR?=	NWPofY9LPzJiaB?=	MXfEUXNQ	NF\mN2dKSzVyPUGwJO69VQ>?	M2rBdlI{QDR2MEO4
NCI-H526	NVS0OYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\EPVExKM7:TR?=	NVPCVnNTPzJiaB?=	MkDsSG1UVw>?	MUfJR\|UxRTFyIN88US=>	NEfzR3IzOzh2NECzPC=>
NCI-H630	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEizZY4yOCEQvF2=	NXHXU4FCPzJiaB?=	MonsSG1UVw>?	MmLzTWM2OD1zMDFOwG0>	MVqyN\|g1PDB\|OB?=
NCI-H661	NVjjVWo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vjS\|ExKM7:TR?=	NYfZTGtvPzJiaB?=	MY\EUXNQ	M133W2lEPTB;MUCg{txO	M3T5V\|I{QDR2MEO4
NCI-H716	MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXLRVI6OTBizszN	NHrWTVU4OiCq	NInWb5VFVVOR	NXXLeIllUUN3ME2xNEDPxE1?	MmTTNlM5PDRyM{i=
NCI-H1563	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP2O2FDOTBizszN	MnezO\|IhcA>?	Ml7CSG1UVw>?	MXHJR\|UxRTFyIN88US=>	MnfVNlM5PDRyM{i=
NCI-H1792	NGf0cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1T2eVExKM7:TR?=	NIDtbIE4OiCq	NYCxWnFGTE2VTx?=	M3;jZWlEPTB;MUCg{txO	M13OeFI{QDR2MEO4
NCI-H2030	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknuNVAh\|ryP	MWm3NkBp	NFfOdmtFVVOR	M2nC[GlEPTB;MUCg{txO	MV2yN\|g1PDB\|OB?=
NCI-H2052	NF7XbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnX5NVAh\|ryP	NG\rOVM4OiCq	NUiwfmRVTE2VTx?=	NYTsXop3UUN3ME2xNEDPxE1?	MnnDNlM5PDRyM{i=
NCI-H2122	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjwNVAh\|ryP	MmXtO\|IhcA>?	NYH3O\|M4TE2VTx?=	NV\ORnBUUUN3ME2xNEDPxE1?	NHzn[2QzOzh2NECzPC=>
NCI-H2228	MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW4d2hPOTBizszN	MlflO\|IhcA>?	M3XpOmROW09?	NVfPSoJZUUN3ME2xNEDPxE1?	NYKzUVJJOjN6NESwN\|g>
OE-19	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYCxNEDPxE1?	MlnMO\|IhcA>?	M4Hyc2ROW09?	NGriOo9KSzVyPUGwJO69VQ>?	MoLtNlM5PDRyM{i=
OE-21	NYG4b5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnK1NVAh\|ryP	M{S2flczKGh?	NGnmW2RFVVOR	NHKxZ5dKSzVyPUGwJO69VQ>?	M4\EfFI{QDR2MEO4
OE-33	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rnNlExKM7:TR?=	MVq3NkBp	NGnvT5BFVVOR	NW\C[ldtUUN3ME2xNEDPxE1?	NGDwSVQzOzh2NECzPC=>
OVCAR-3	NFvFNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmW5NVAh\|ryP	M2fiSVczKGh?	NXnXdJN5TE2VTx?=	M3fORmlEPTB;MUCg{txO	NUC3SI1NOjN6NESwN\|g>
OVCAR-4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWKxNEDPxE1?	NYK4WplSPzJiaB?=	MlzaSG1UVw>?	MXHJR\|UxRTFyIN88US=>	MkLlNlM5PDRyM{i=
OVCAR-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rhU\|ExKM7:TR?=	MXm3NkBp	NG\idHhFVVOR	Mnj1TWM2OD1zMDFOwG0>	MUWyN\|g1PDB\|OB?=
P3HR-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLtT5kyOCEQvF2=	NVPST28xPzJiaB?=	M1TJTGROW09?	MkTvTWM2OD1zMDFOwG0>	M1jrZ\|I{QDR2MEO4
PC-3	Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSxNEDPxE1?	MUK3NkBp	M3[2N2ROW09?	NXzQNG5FUUN3ME2xNEDPxE1?	NHjUUlQzOzh2NECzPC=>
Raji	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PPTFExKM7:TR?=	NWXr[oZ4PzJiaB?=	NXXJUFA4TE2VTx?=	NXjCZnhUUUN3ME2xNEDPxE1?	MUeyN\|g1PDB\|OB?=
RD	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfSXIkyOCEQvF2=	M1z3blczKGh?	NF\nNW5FVVOR	NU[1XmtrUUN3ME2xNEDPxE1?	MX2yN\|g1PDB\|OB?=
RD-ES	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHKNVAh\|ryP	NGH5eXk4OiCq	MVnEUXNQ	Mn\VTWM2OD1zMDFOwG0>	Ml64NlM5PDRyM{i=
RL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmxNEDPxE1?	NXzse45IPzJiaB?=	M3nBU2ROW09?	MoDUTWM2OD1zMDFOwG0>	NV;DS4J[OjN6NESwN\|g>
SaOS2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnO5NVAh\|ryP	NEW2S3Y4OiCq	NF7HfHRFVVOR	MlrQTWM2OD1zMDFOwG0>	MXyyN\|g1PDB\|OB?=
SCC-9	NHLmZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2xNEDPxE1?	Mkj6O\|IhcA>?	MYrEUXNQ	NGHobIVKSzVyPUGwJO69VQ>?	MX6yN\|g1PDB\|OB?=
SCC-12	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNEDPxE1?	NYTJcHQ{PzJiaB?=	M3TlU2ROW09?	NVPCfllUUUN3ME2xNEDPxE1?	NV;sZ5dzOjN6NESwN\|g>
SCC-13	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf4PHAyOCEQvF2=	NYPxUXE1PzJiaB?=	MUHEUXNQ	NUPVdJFYUUN3ME2xNEDPxE1?	MWqyN\|g1PDB\|OB?=
SCC-15	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxNEDPxE1?	NHnFOlQ4OiCq	MnTRSG1UVw>?	M1ruV2lEPTB;MUCg{txO	NFrRWWkzOzh2NECzPC=>
SCC-25	M3XKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX[yc3N7OTBizszN	M2m5NVczKGh?	MX3EUXNQ	MlzYTWM2OD1zMDFOwG0>	NHXEd5gzOzh2NECzPC=>
SCLC-3	NVzUc25TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofvNVAh\|ryP	MWK3NkBp	Mn7BSG1UVw>?	NWHFV5hlUUN3ME2xNEDPxE1?	MWGyN\|g1PDB\|OB?=
SF-268	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\UNVAh\|ryP	MmLiO\|IhcA>?	MVHEUXNQ	NULMNGZwUUN3ME2xNEDPxE1?	MWmyN\|g1PDB\|OB?=
SF-295	NVLKRoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HXV\|ExKM7:TR?=	M1jYVFczKGh?	NFP0d4pFVVOR	NWWwZYxQUUN3ME2xNEDPxE1?	MlTjNlM5PDRyM{i=
SJRH30	NFHzW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXIXpNvOTBizszN	MYe3NkBp	MUnEUXNQ	MYnJR\|UxRTFyIN88US=>	NEGzRogzOzh2NECzPC=>
SK-BR-3	NYTnUI03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzSTpUyOCEQvF2=	MYO3NkBp	MkLkSG1UVw>?	MXvJR\|UxRTFyIN88US=>	NFfXUYczOzh2NECzPC=>
SK-LMS-1	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUKxNEDPxE1?	MWW3NkBp	NF3JS3JFVVOR	NHG1PZVKSzVyPUGwJO69VQ>?	MVyyN\|g1PDB\|OB?=
SK-N-DZ	NILROW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHKNVAh\|ryP	MVe3NkBp	NH23WmpFVVOR	NEXWNY9KSzVyPUGwJO69VQ>?	MnSzNlM5PDRyM{i=
SK-N-F1	NELXTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnHNVAh\|ryP	MY[3NkBp	NIjOTIdFVVOR	MYTJR\|UxRTFyIN88US=>	MV[yN\|g1PDB\|OB?=
SKOV-3	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;MTFExKM7:TR?=	M3HIblczKGh?	MkS4SG1UVw>?	NXrPclhOUUN3ME2xNEDPxE1?	MWOyN\|g1PDB\|OB?=
SK-UT-1	M37NPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXu3UJJDOTBizszN	MVi3NkBp	M1LwUWROW09?	NYDsTo5oUUN3ME2xNEDPxE1?	NInVRY8zOzh2NECzPC=>
SN12C	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTaW2oyOCEQvF2=	NHjXcmY4OiCq	M4TLZ2ROW09?	M4DOVGlEPTB;MUCg{txO	MlixNlM5PDRyM{i=
SNB-19	NIXPOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\v[moyOCEQvF2=	NXzUdZFzPzJiaB?=	MX3EUXNQ	NXHuXmRRUUN3ME2xNEDPxE1?	NVnwOWNDOjN6NESwN\|g>
SNU-5	M3u4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWxNEDPxE1?	M2TGR\|czKGh?	NFjwOohFVVOR	MVfJR\|UxRTFyIN88US=>	MWSyN\|g1PDB\|OB?=
SNU-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mne0NVAh\|ryP	MUG3NkBp	NFf0ZnlFVVOR	NEfnV4FKSzVyPUGwJO69VQ>?	MWeyN\|g1PDB\|OB?=
SNU-398	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoK2NVAh\|ryP	NXfvb3pVPzJiaB?=	Mlu1SG1UVw>?	M4\DXWlEPTB;MUCg{txO	NHfUOm8zOzh2NECzPC=>
SNU-449	NVfPT2lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL5OXEyOCEQvF2=	NVXKPZA4PzJiaB?=	NIPzVHJFVVOR	NUPzUlQ2UUN3ME2xNEDPxE1?	MlTBNlM5PDRyM{i=
SR	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzTZ2IyOCEQvF2=	NYnwcYhiPzJiaB?=	NIe0bHZFVVOR	M13oOmlEPTB;MUCg{txO	NUDO[ml6OjN6NESwN\|g>
ST486	M1e2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn4XJQyOCEQvF2=	NXXxT5Q3PzJiaB?=	NHvwWWtFVVOR	NUPTemxPUUN3ME2xNEDPxE1?	M4LiXFI{QDR2MEO4
SW579	MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrNNVAh\|ryP	NXHpbmF{PzJiaB?=	MmrtSG1UVw>?	MnnaTWM2OD1zMDFOwG0>	NYK4XmF[OjN6NESwN\|g>
SW684	NX3DR4Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfyNVAh\|ryP	NH[5TZA4OiCq	NH7scnlFVVOR	MlfLTWM2OD1zMDFOwG0>	NYPVO4J5OjN6NESwN\|g>
SW-780	NY\pdZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	MYO3NkBp	M1;lc2ROW09?	NF3jcIxKSzVyPUGwJO69VQ>?	MkDzNlM5PDRyM{i=
SW900	NHn0SnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWC0RmpWOTBizszN	NHq2cnU4OiCq	M4WyUWROW09?	NIDTS5FKSzVyPUGwJO69VQ>?	MVSyN\|g1PDB\|OB?=
SW1088	NUj5S3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7RNVAh\|ryP	MUG3NkBp	MUfEUXNQ	MlW5TWM2OD1zMDFOwG0>	NYi3TZNnOjN6NESwN\|g>
SW1463	NGrGW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTFfHZUOTBizszN	NX7CT4R2PzJiaB?=	Mkn3SG1UVw>?	NF6xNnNKSzVyPUGwJO69VQ>?	MV2yN\|g1PDB\|OB?=
SW1990	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Tzb\|ExKM7:TR?=	MUW3NkBp	NID3T5pFVVOR	NXLnTYJLUUN3ME2xNEDPxE1?	M130dFI{QDR2MEO4
T47D	NXvHU5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	MmnwO\|IhcA>?	NXu5VJB[TE2VTx?=	Mmn3TWM2OD1zMDFOwG0>	MnvMNlM5PDRyM{i=
TE381.T	NEnOVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxNEDPxE1?	M3fJRVczKGh?	M1vkRWROW09?	M3H6SmlEPTB;MUCg{txO	M1iydFI{QDR2MEO4
TK-10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnrOXZtOTBizszN	MojEO\|IhcA>?	MmjOSG1UVw>?	NYrCVHlUUUN3ME2xNEDPxE1?	M376fVI{QDR2MEO4
U2OS	NIHpfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXixNEDPxE1?	MlrIO\|IhcA>?	NHvnTVVFVVOR	Mn;wTWM2OD1zMDFOwG0>	MXiyN\|g1PDB\|OB?=
U251	Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfaNVAh\|ryP	MmD3O\|IhcA>?	M3vGTWROW09?	NUi5SWUxUUN3ME2xNEDPxE1?	NIizcoszOzh2NECzPC=>
UACC-812	NGm5XHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYS0NpVNOTBizszN	M1PS[VczKGh?	M1jifmROW09?	NUTpXm1oUUN3ME2xNEDPxE1?	MX:yN\|g1PDB\|OB?=
YAPC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxNEDPxE1?	MmK5O\|IhcA>?	NEjKPWZFVVOR	NVr1bXRKUUN3ME2xNEDPxE1?	MUKyN\|g1PDB\|OB?=
ZR-75-1	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHv4PVEyOCEQvF2=	NGLob2o4OiCq	M3fEPGROW09?	Moi0TWM2OD1zMDFOwG0>	M{PKN\|I{QDR2MEO4
A375	M1[5UWZ2dmO2aX;uJIF{e2G7	MnvpNU4zKM7:TR?=	NF\PNmQ1KGh?	NIP3VmNFVVOR	NGPsdlJKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?=	MX:yNlM5QTR5MR?=
YUSIT1	M4H6XWZ2dmO2aX;uJIF{e2G7			MnHnSG1UVw>?	M3jKZ5Jm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR\|UxKD5iMD61JO69VQ>?	NGLPfIgzOjN6OUS3NS=>
MeWo	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M2PmZ2ROW09?	NXzoPGlsUUN3MDC9JFk5PyCwTR?=	M{T6eFI3ODF6NUK0
WiDr	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MmS1SG1UVw>?	NX;CSoFHUUN3MDC9JFc3KG6P	NYG5bnBsOjZyMUi1NlQ>
Colo-205	MVHGeY5kfGmxbjDhd5NigQ>?	MXWxJO69VQ>?	M2jrclQh\A>?	MWrEUXNQ	NYDHemxwUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn	M1PPWlI2OzhzMUWy
RBW-1	NF\ue4lHfW6ldHnvckBie3OjeR?=	NH;LUJQyKM7:TR?=		NEi3eoNFVVOR	NVjxS4J[Vm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w	MYCyOFg5PTZ7MB?=
RBO-1	M2LRbmZ2dmO2aX;uJIF{e2G7	MoO2NUDPxE1?		M4r2fWROW09?	NYLU[mRrUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NV7he2RTOjR6OEW2PVA>
RBO-2	NF60bYNHfW6ldHnvckBie3OjeR?=	Mk\0NUDPxE1?		MY\EUXNQ	NF3EdlVKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	MX6yOFg5PTZ7MB?=
RBOW	NWDBeYhETnWwY4Tpc44h[XO\|YYm=	NVrjUndzOSEQvF2=		MYTEUXNQ	NXjtU29DUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	NGrJNGYzPDh6NU[5NC=>
M257	NU\wR5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVyxNFAhdk1?	MY[3NkBp		MmXQSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI	MkfKNlM{OTd2NE[=
LCP	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvhNVAxKG6P	MWe3NkBp		NYf2OIZvUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MUKyN\|MyPzR2Nh?=
WM266	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxNFAhdk1?	M4P2OVczKGh?		M{DE[mlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>?	M2r5UVI{OzF5NES2
M257	M2HTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1iweVExOCCwTR?=	NGDjfW84OiCq		NGDpbplFd2W\|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NYDxNHZZOjN\|MUe0OFY>
LCP	NE\YPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnocWFYOTByIH7N	NVHCPItmPzJiaB?=		MXrJcohq[mm2IFXST\|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	NGHmXXczOzNzN{S0Oi=>
WM266	NFnhNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[xNFAhdk1?	MWm3NkBp		NHLFeG9KdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36=	M2HkS\|I{OzF5NES2

... Click to View More Cell Line Experimental Data

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03272464	Recruiting	Melanoma	Massachusetts General Hospital\|Incyte Corporation	November 30 2018	Phase 1
NCT03668431	Recruiting	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT02672358	Withdrawn	Non-Small-Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	September 3 2018	Phase 2
NCT03551626	Recruiting	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	August 29 2018	Phase 3
NCT03455764	Recruiting	Melanoma	Dana-Farber Cancer Institute\|Novartis	June 22 2018	Phase 1\|Phase 2
NCT03553329	Completed	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products3

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523, VRT752271) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 21 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)

Cited by 21 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dabrafenib (GSK2118436) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)